Sustained DRSS improvement with aflibercept
October 16, 2019
Treating diabetic retinopathy (DR) with anti-vascular endothelial growth factor (VEGF) agents is an alternative to panretinal laser, and in some studies it has been found that “
Recent Content
Several cyst characteristics linked to ischemia in DME
September 30, 2019
ASRS 2019 Street Team: Dr. Rishi Singh
September 20, 2019
Dr. Rishi Singh discusses the launch of Alcon's HYPERVIT.
Dr. Singh is a paid Alcon consultant.
ASRS 2019 Street Team: Josh Anderson
September 20, 2019
Josh Anderson, head of Alcon's U.S. Surgical Retina Sales & Marketing, discusses how the NGENUITY 3D Visualization System creates an immersive surgical experience.
SWAP-TWO shows anatomic improvement after switch to aflibercept
September 17, 2019
For patients with diabetic macular edema (DME), intravitreal anti-vascular endothelial growth factor (VEGF) agents have become the first-line treatment.
ASRS 2019 Street Team: Chuck Hess
September 4, 2019
ICYMI: Chuck Hess, vice president and general manager of the U.S. Surgical Divison at Bausch + Lomb, shares what's in the company's surgical pipeline at the 2019 annual American Society of Retina Specialists meeting in Chicago.
ASRS 2019 Street Team: W. Lloyd Clark, MD
August 29, 2019
ICYMI: Dr. Clark breaks down the results of the PANORAMA Study
ASRS 2019 Street Team: Rishi P. Singh, MD
August 28, 2019
ICYMI: Dr. Singh shares the take-home message from his 2019 presentation
ASRS 2019 Street Team: Charles C. Wykoff, MD, PhD
August 28, 2019
ICMYI: Dr. Wykoff discusses results from his ASRS presentation
Meta-analysis on DME treatments updated to include treatment regimen
August 27, 2019
The choice of which anti-vascular endothelial growth factor (VEGF) agent to use on patients with diabetic macular edema (DME) may depend on a variety of variables, including b
